Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Looking back to 160 days ago, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) priced a 14,300,000 share secondary stock offering at $3.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -3.75% in last session and finished the … Continue reading Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Kristen Barton04/0304/03

FB Nasdaq FB Facebook

Diversified Tech

Healthcare Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squib (NYSE:BMY), Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Congress jumped into the health care game (again) by “complaining” that Gilead Sciences, Inc. (NASDAQ:GILD)’s hepatitis drug was priced too high. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.92% in last session and finished the day at $73.64. Traded volume was 19.50million shares in the last session and the average volume of the stock remained 13.29million shares. The beta of the stock remained 0.55. Gilead … Continue reading Healthcare Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squib (NYSE:BMY), Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Jason Knox04/0204/02

Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) was active yesterday as one Bloomberg reporter thinks he has another take on the recent Waxman letter. Drew Armstrong — via his own Twitter account — said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to drag them in. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.37% in … Continue reading Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Mark DeFrance04/0104/01

Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Merck & Co., Inc. (NYSE:MRK) is getting close to conducting phase 3 trials for a combination treatment for Hepatitis C, which could potentially rejuvenate the pharmaceutical giant’s revenue growth. The clinical data for a combination of drugs MK-5172 and MK-8742 has showed high cure rates among patients with genotype 1 of the disease, and this has encouraged Merck to move to phase 3 trials. Merck … Continue reading Healthcare Active Runners: Merck & Co. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Ariad Pharmaceuticals (NASDAQ:ARIA)

Kevin Long03/3103/31

FB Nasdaq FB Facebook

Biotech Bullish Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Idera Pharmaceuticals (NASDAQ:IDRA), CytRx Corporation (NASDAQ:CYTR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is 6.6% higher, as traders digest rumors that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was willing to pay over $20 per share to buy the firm. Digging deeper, speculators are expecting ARIA to remain south of $9 in the short term, buying to open the April 9 and May 9 puts. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 5.00% in last session and … Continue reading Biotech Bullish Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Idera Pharmaceuticals (NASDAQ:IDRA), CytRx Corporation (NASDAQ:CYTR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Jason Knox03/3103/31

Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the … Continue reading Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Jayne Crisman03/2703/27